PET for Therapeutic Response Monitoring in Oncology

PET Clinics

Volumn 3, Issue 1, 2008, Pages 89-99

  Hicks, Rodney J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Cancer; FDG; PET; SUV; Therapeutic monitoring

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; FLUOROETHYLTYROSINE F 18; GALLIUM 68; IMATINIB; IODINE 124; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 86;

CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; DRUG DISTRIBUTION; DRUG UPTAKE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; METABOLIC DISORDER; NEOPLASM; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; WHOLE BODY TOMOGRAPHY;

EID: 64749104357     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2008.09.003     Document Type: Review

References (68)

1. Cachin F., Prince H.M., Hogg A., et al. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 24 19 (2006) 3026-3031
2. Eckhardt S. Molecular targeted therapy: a strategy of disillusions or optimism?. J Lab Clin Med 147 3 (2006) 108-113
3. Jones L.A., Chilton J.A., Hajek R.A., et al. Between and within: international perspectives on cancer and health disparities. J Clin Oncol 24 14 (2006) 2204-2208
4. Therasse P., Eisenhauer E.A., and Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42 8 (2006) 1031-1039
5. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 1 (1981) 207-214
6. Moertel C.G., and Hanley J.A. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38 1 (1976) 388-394
7. Jaffe C.C. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24 20 (2006) 3245-3251
8. Barnacle A.M., and McHugh K. Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy. Pediatr Blood Cancer 46 2 (2006) 127-134
9. Kelloff G.J., Hoffman J.M., Johnson B., et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11 8 (2005) 2785-2808
10. Pantaleo M.A., Saponara M., Nannini M., et al. Targeted therapies in solid tumours: results and promises. Minerva Medicoleg 98 5 (2007) 603-623
11. Gambhir S.S., Czernin J., Schwimmer J., et al. A tabulated summary of the FDG PET literature. J Nucl Med 42 5 Suppl (2001) 1S-93S
12. Czernin J., Allen-Auerbach M., and Schelbert H.R. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 48 Suppl 1 (2007) 78S-88S
13. Weber W.A., and Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference?. J Nucl Med 48 Suppl 1 (2007) 36S-44S
14. Ichiya Y., Kuwabara Y., Otsuka M., et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 32 9 (1991) 1655-1660
15. Wahl R.L., Zasadny K., Helvie M., et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11 11 (1993) 2101-2111
16. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18f]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European organization for research and treatment of cancer (EORTC) PET study group. Eur J Cancer 35 13 (1999) 1773-1782
17. Shankar L.K., Hoffman J.M., Bacharach S., et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. J Nucl Med 47 6 (2006) 1059-1066
18. Mac Manus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell. J Clin Oncol 21 7 (2003) 1285-1292
19. Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45 9 (2004) 1431-1434
20. Minn H., Zasadny K.R., Quint L.E., et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 196 1 (1995) 167-173
21. Weber W.A., Ziegler S.I., Thodtmann R., et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40 11 (1999) 1771-1777
22. Nahmias C., Hanna W.T., Wahl L.M., et al. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J Nucl Med 48 5 (2007) 744-751
23. Larson S.M., Erdi Y., Akhurst T., et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. the visual response score and the change in total lesion glycolysis. Clin Positron Imaging 2 3 (1999) 159-171
24. Francis R.J., Byrne M.J., van der Schaaf A.A., et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 48 9 (2007) 1449-1458
25. Van den Abbeele A.D., and Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38 Suppl 5 (2002) S60-S65
26. Stroobants S., Goeminne J., Seegers M., et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39 14 (2003) 2012-2020
27. Holdsworth C.H., Badawi R.D., Manola J.B., et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 189 6 (2007) W324-W330
28. Juweid M.E., Stroobants S., Hoekstra O.S., et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25 5 (2007) 571-578
29. Hicks R.J., MacManus M.P., Matthews J.P., et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60 2 (2004) 412-418
30. MacManus M.P., Hicks R.J., Matthews J.P., et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer. 49 1 (2005) 95-108
31. Duong C.P., Hicks R.J., Weih L., et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging 33 7 (2006) 770-778
32. Kalff V., Duong C., Drummond E.G., et al. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 47 1 (2006) 14-22
33. Connell C.A., Corry J., Milner A.D., et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 29 11 (2007) 986-995
34. Specht J.M., Tam S.L., Kurland B.F., et al. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 105 1 (2007) 87-94
35. Hutchings M., Mikhaeel N.G., Fields P.A., et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16 7 (2005) 1160-1168
36. Wieder H.A., Brucher B.L., Zimmermann F., et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22 5 (2004) 900-908
37. Rousseau C., Devillers A., Sagan C., et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24 34 (2006) 5366-5372
38. Berriolo-Riedinger A., Touzery C., Riedinger J.M., et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34 12 (2007) 1915-1924
39. Capirci C., Rampin L., Erba P.A., et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 34 10 (2007) 1583-1593
40. MacManus M.P., Seymour J.F., and Hicks R.J. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging 7 (2007) 10-18
41. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cellule 100 1 (2000) 57-70
42. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 11 (1998) 1334-1336
43. Buck A.K., Halter G., Schirrmeister H., et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44 9 (2003) 1426-1431
44. Vesselle H., Grierson J., Muzi M., et al. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8 11 (2002) 3315-3323
45. Kenny L., Coombes R.C., Vigushin D.M., et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[(18)F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34 9 (2007) 1339-1347
46. Hicks R.J. The SUV, FLT PET: a tasty alphabet soup or a dog's breakfast?. Leuk Lymphoma. 48 4 (2007) 649-652
47. Langen K.J., Hamacher K., Weckesser M., et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33 3 (2006) 287-294
48. Price D.T., Coleman R.E., Liao R.P., et al. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168 1 (2002) 273-280
49. Hofmann M., Maecke H., Borner R., et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28 12 (2001) 1751-1757
50. Linden H.M., Stekhova S.A., Link J.M., et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24 18 (2006) 2793-2799
51. Kunkel M., Forster G.J., Reichert T.E., et al. Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma. Oral Oncol. 39 2 (2003) 170-177
52. Ware R.E., Matthews J.P., Hicks R.J., et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck 26 12 (2004) 1008-1017
53. Brun E., Kjellen E., Tennvall J., et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24 2 (2002) 127-135
54. Enomoto K., Inohara H., Higuchi I., et al. Prognostic value of FDG-PET in patients with oropharyngeal carcinoma treated with concurrent chemoradiotherapy. Mol Imaging Biol 10 4 (2008) 224-229
55. Yen R.F., Chen T.H., Ting L.L., et al. Early restaging whole-body (18)F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 32 10 (2005) 1152-1159
56. Hellwig D., Groschel A., Graeter T.P., et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging 33 1 (2006) 13-21
57. Weber W.A., Petersen V., Schmidt B., et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21 14 (2003) 2651-2657
58. de Geus-Oei L.F., van der Heijden H.F., Visser E.P., et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 48 10 (2007) 1592-1598
59. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13 3 (2002) 361-368
60. Swisher S.G., Maish M., Erasmus J.J., et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78 4 (2004) 1152-1160 [discussion: 1152-60]
61. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19 12 (2001) 3058-3065
62. Brucher B.L., Weber W., Bauer M., et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233 3 (2001) 300-309
63. Wieder H.A., Ott K., Lordick F., et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 34 12 (2007) 1925-1932
64. Ott K., Weber W.A., Lordick F., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24 (2006) 4692-4698
65. Ott K., Fink U., Becker K., et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21 24 (2003) 4604-4610
66. Dose Schwarz J., Bader M., Jenicke L., et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 46 7 (2005) 1144-1150
67. Grigsby P.W., Siegel B.A., Dehdashti F., et al. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 55 4 (2003) 907-913
68. Schuetze S.M., Rubin B.P., Vernon C., et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 103 2 (2005) 339-348